Qelbree fda approval?

Short answer:
- Yes. Qelbree (viloxazine hydrochloride) extended‑release was FDA‑approved on April 29, 2021 for treating ADHD in children and adolescents aged 6 to 17.

What to know:
- Mechanism: Non-stimulant ADHD medication. Viloxazine is a norepinephrine reuptake inhibitor with a unique profile compared to stimulants.
- Age indication: Approved only for ages 6–17 (as of the latest updates; not approved for adults yet).
- Dosing (typical): Often started at 100 mg once daily and can be titrated up to 400 mg daily based on response and tolerability. Take as directed by a clinician (usually once daily in the morning).
- Safety: As with ADHD meds, there is a risk of behavioral changes or suicidality in children/adolescents; monitor for mood changes, sleep problems, appetite changes, irritability, or new or worsening anxiety. Avoid use with monoamine oxidase inhibitors (MAOIs) and follow physician guidance on use with other meds.
- Where to check: Official FDA labeling for Qelbree provides detailed dosing, safety, and usage information.

If you want, I can pull together a concise comparison of Qelbree with a couple of other ADHD non-stimulant options (like Strattera) or check for any updates on adult approvals.